Abstract
Objective: Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes. The objective of the present study was to retard the release of metformin using carrier erythrocyte for getting a parenteral slow release depot formulation.Methods: The study retards the release of metformin by encapsulating in carier erythrocyte. Endocytosis is the method used for the encapsulation of the drug metormin.Results: The optimized formulation shows 98.34% of drug release within 12 days. From the invitro release data zero order kinetic graph shows the best fit graph. % cell recovered was found to be 73-78% and it suggests that the loading technique was less destructive.Conclusion: The optimized formulation is a perfect carrier for the parenteral slow release depot of metformin.Keywords: Resealed erythrocytes, cross linking, cell recovery, endocytosis, slow release depot formulation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
